Former British Army Chief Calls for Eased MDMA Regulations to Treat Veterans' PTSD
A high-ranking former British military officer is urging the government to relax restrictions on the party drug MDMA in order to facilitate cheaper trials of its use as a treatment for post-traumatic stress disorder (PTSD) among veterans.
Sir Nick Carter, who served as chief of the defense staff until 2021, believes that existing regulations are stifling research into the potential benefits of MDMA-assisted therapy. Currently, a single gram of "medical-grade" MDMA can cost up to £10,000, compared with a street price of around £40, making it prohibitively expensive for researchers to conduct trials.
Carter argues that these restrictions are limiting the ability to test MDMA in clinical settings and prevent its potential effectiveness from being fully realized. A recent study published in Nature Medicine found that 71% of participants who underwent MDMA-assisted therapy experienced complete elimination of PTSD symptoms. Carter is calling on the government to reduce these costs, not by decriminalizing the drug but rather by relaxing its classification for medical use.
The charity Supporting Wounded Veterans, which Carter patronizes, is seeking £2 million to fund further trials of MDMA-assisted therapy. While £700,000 has already been raised, more funding is needed to support this research.
One individual who could benefit from such treatment is Martin Wade, a former British Army lawyer who was deployed in Afghanistan and later developed PTSD. Wade described feeling increasingly responsible for the decisions made on the ground during his deployment, including deciding whether a soldier's actions constituted a war crime.
Wade struggled with mental health issues following his discharge from the military, including hyper-vigilance, flashbacks, and nightmares. He believes that MDMA-assisted therapy could offer hope to veterans struggling with PTSD but has been unable to find relief through conventional treatments.
The potential benefits of MDMA-assisted therapy extend beyond the military community. Carter suggests that this treatment could also be beneficial for police officers, emergency services workers, and NHS personnel who may experience similar levels of stress and trauma.
As research into the therapeutic potential of MDMA continues, it remains to be seen whether these proposed trials will ultimately contribute to a reduction in PTSD symptoms among veterans.
A high-ranking former British military officer is urging the government to relax restrictions on the party drug MDMA in order to facilitate cheaper trials of its use as a treatment for post-traumatic stress disorder (PTSD) among veterans.
Sir Nick Carter, who served as chief of the defense staff until 2021, believes that existing regulations are stifling research into the potential benefits of MDMA-assisted therapy. Currently, a single gram of "medical-grade" MDMA can cost up to £10,000, compared with a street price of around £40, making it prohibitively expensive for researchers to conduct trials.
Carter argues that these restrictions are limiting the ability to test MDMA in clinical settings and prevent its potential effectiveness from being fully realized. A recent study published in Nature Medicine found that 71% of participants who underwent MDMA-assisted therapy experienced complete elimination of PTSD symptoms. Carter is calling on the government to reduce these costs, not by decriminalizing the drug but rather by relaxing its classification for medical use.
The charity Supporting Wounded Veterans, which Carter patronizes, is seeking £2 million to fund further trials of MDMA-assisted therapy. While £700,000 has already been raised, more funding is needed to support this research.
One individual who could benefit from such treatment is Martin Wade, a former British Army lawyer who was deployed in Afghanistan and later developed PTSD. Wade described feeling increasingly responsible for the decisions made on the ground during his deployment, including deciding whether a soldier's actions constituted a war crime.
Wade struggled with mental health issues following his discharge from the military, including hyper-vigilance, flashbacks, and nightmares. He believes that MDMA-assisted therapy could offer hope to veterans struggling with PTSD but has been unable to find relief through conventional treatments.
The potential benefits of MDMA-assisted therapy extend beyond the military community. Carter suggests that this treatment could also be beneficial for police officers, emergency services workers, and NHS personnel who may experience similar levels of stress and trauma.
As research into the therapeutic potential of MDMA continues, it remains to be seen whether these proposed trials will ultimately contribute to a reduction in PTSD symptoms among veterans.